These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 17272316)
1. The role of the outpatient clinic in chemotherapy for patients with unresectable or recurrent gastric cancer. Yamazaki K; Boku N; Shibamoto K; Yasui H; Fukutomi A; Yoshino T; Hironaka S; Onozawa Y; Otake Y; Hasuike N; Matsubayashi H; Inui T; Yamaguchi Y; Ono H Jpn J Clin Oncol; 2007 Feb; 37(2):96-101. PubMed ID: 17272316 [TBL] [Abstract][Full Text] [Related]
2. Duration of chemotherapy with topotecan influences survival in recurrent ovarian cancer: a meta-analysis. Möbus V; Kieback DG; Kaubitzsch SK Anticancer Res; 2007; 27(3B):1581-7. PubMed ID: 17595779 [TBL] [Abstract][Full Text] [Related]
3. High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system. Gill P; Litzow M; Buckner J; Arndt C; Moynihan T; Christianson T; Ansell S; Galanis E Cancer; 2008 Apr; 112(8):1805-11. PubMed ID: 18300237 [TBL] [Abstract][Full Text] [Related]
4. A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer. Nakajo A; Hokita S; Ishigami S; Miyazono F; Etoh T; Hamanoue M; Maenohara S; Iwashita T; Komatsu H; Satoh K; Aridome K; Morita S; Natsugoe S; Takiuchi H; Nakano S; Maehara Y; Sakamoto J; Aikou T; Cancer Chemother Pharmacol; 2008 Nov; 62(6):1103-9. PubMed ID: 18317763 [TBL] [Abstract][Full Text] [Related]
5. Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer. Inada S; Tomidokoro T; Fukunari H; Sato T; Hatano T; Nishimura A; Kawauchi Y; Nikkuni K; Shimizu T; Sato T; Yanagi M; Takahashi S; Yoshida H; Sugita M; Hayashi T Cancer Chemother Pharmacol; 2009 Jan; 63(2):267-73. PubMed ID: 18379784 [TBL] [Abstract][Full Text] [Related]
6. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial. Koizumi W; Akiya T; Sato A; Yamaguchi K; Sakuyama T; Nakayama N; Tanabe S; Higuchi K; Sasaki T; Sekikawa T; Jpn J Clin Oncol; 2009 Nov; 39(11):713-9. PubMed ID: 19812061 [TBL] [Abstract][Full Text] [Related]
7. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Kim JG; Ryoo BY; Park YH; Kim BS; Kim TY; Im YH; Kang YK Cancer Chemother Pharmacol; 2008 Feb; 61(2):301-7. PubMed ID: 17429626 [TBL] [Abstract][Full Text] [Related]
8. Combination chemotherapy of S-1 and low-dose twice-weekly cisplatin for advanced and recurrent gastric cancer in an outpatient setting: a retrospective study. Tsuji A; Shima Y; Morita S; Uchida M; Okamoto K; Morita M; Horimi T; Shirasaka T Anticancer Res; 2008; 28(2B):1433-8. PubMed ID: 18505092 [TBL] [Abstract][Full Text] [Related]
9. Hepatic arterial infusion combined with oral UFT/UZEL systemic chemotherapy for unresectable liver metastasis of colorectal cancer. Tsutsumi S; Yamaguchi S; Tsuboi K; Fukasawa T; Tabe Y; Asao T; Kuwano H Hepatogastroenterology; 2008; 55(85):1419-22. PubMed ID: 18795703 [TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. Di Costanzo F; Gasperoni S; Manzione L; Bisagni G; Labianca R; Bravi S; Cortesi E; Carlini P; Bracci R; Tomao S; Messerini L; Arcangeli A; Torri V; Bilancia D; Floriani I; Tonato M; ; Dinota A; Strafiuso G; Corgna E; Porrozzi S; Boni C; Rondini E; Giunta A; Monzio Compagnoni B; Biagioni F; Cesari M; Fornarini G; Nelli F; Carboni M; Cognetti F; Enzo MR; Piga A; Romiti A; Olivetti A; Masoni L; De Stefanis M; Dalla Mola A; Camera S; Recchia F; De Filippis S; Scipioni L; Zironi S; Luppi G; Italia M; Banducci S; Pisani Leretti A; Massidda B; Ionta MT; Nicolosi A; Canaletti R; Biscottini B; Grigniani F; Di Costanzo F; Rovei R; Croce E; Carroccio R; Gilli G; Cavalli C; Olgiati A; Pandolfi U; Rossetti R; Natalini G; Foa P; Oldani S; Bruno L; Cascinu S; Catalano G; Catalano V; Lungarotti F; Farris A; Sarobba MG; Trignano M; Muscogiuri A; Francavilla F; Figoli F; Leoni M; Papiani G; Orselli G; Antimi M; Bellini V; Cabassi A; Contu A; Pazzola A; Frignano M; Lastraioli E; Saggese M; Bianchini D; Antonuzzo L; Mela M; Camisa R J Natl Cancer Inst; 2008 Mar; 100(6):388-98. PubMed ID: 18334706 [TBL] [Abstract][Full Text] [Related]
11. A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial. Hamaguchi T; Shirao K; Yamamichi N; Hyodo I; Koizumi W; Seki S; Imamura T; Honma H; Ohtsu A; Boku N; Mukai T; Yamamoto S; Fukuda H; Yoshida S; Jpn J Clin Oncol; 2008 Jun; 38(6):432-7. PubMed ID: 18515821 [TBL] [Abstract][Full Text] [Related]
12. A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer. Lee JJ; Kim SY; Chung HC; Lee KH; Song HS; Kang WK; Hong YS; Choi IS; Lee YY; Woo IS; Choi JH Cancer Chemother Pharmacol; 2009 May; 63(6):1083-90. PubMed ID: 18813927 [TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma. Lim JY; Cho JY; Oh KJ; Choi SH; Lee SI; Jeung HC Chemotherapy; 2009; 55(4):200-6. PubMed ID: 19451710 [TBL] [Abstract][Full Text] [Related]
14. Phase II study of weekly paclitaxel and cisplatin combination therapy for advanced or recurrent gastric cancer. Nagata N; Kimura M; Hirabayashi N; Tuburaya A; Murata T; Kondo K; Fukuda Y; Kobayashi M; Miyashita Y; Nakao A; Sakamoto J Hepatogastroenterology; 2008; 55(86-87):1846-50. PubMed ID: 19102406 [TBL] [Abstract][Full Text] [Related]
15. [Administration of S-1 after gastrojejunostomy for unresectable gastric cancer with pyloric stenosis]. Nishikawa K; Iwase K; Fujii M; Matsuda C; Shimada K; Hirota M; Kimura T; Wada D; Nasu S; Tanaka Y Gan To Kagaku Ryoho; 2009 Apr; 36(4):595-8. PubMed ID: 19381030 [TBL] [Abstract][Full Text] [Related]
16. Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer: Korea Japan Collaborative Study Group Trial. Kim YH; Yamaguchi K; Bang YJ; Takiuchi H; Kang WK; Sato A; Kang YK; Sakamoto J; Abe C; Sakata Y Jpn J Clin Oncol; 2007 Jul; 37(7):501-8. PubMed ID: 17673470 [TBL] [Abstract][Full Text] [Related]
17. Indicators of survival duration in ovarian cancer and implications for aggressiveness of care. von Gruenigen V; Daly B; Gibbons H; Hutchins J; Green A Cancer; 2008 May; 112(10):2221-7. PubMed ID: 18348300 [TBL] [Abstract][Full Text] [Related]
18. Feasibility of self-expandable metallic stent plus chemotherapy for metastatic gastric cancer with pyloric stenosis. Shimura T; Kataoka H; Sasaki M; Yamada T; Hayashi K; Togawa S; Okumura F; Kubota E; Ohara H; Joh T J Gastroenterol Hepatol; 2009 Aug; 24(8):1358-64. PubMed ID: 19467141 [TBL] [Abstract][Full Text] [Related]
19. [Present status and prospects for chemotherapy for advanced or recurrent gastric cancer in our hospital]. Yamamoto M; Matsuyama A; Emi Y; Yano S; Kameyama T; Okamoto M; Kuma S; Utsunomiya T; Ishida T Gan To Kagaku Ryoho; 2008 Mar; 35(3):441-4. PubMed ID: 18347393 [TBL] [Abstract][Full Text] [Related]
20. Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer. Kim HJ; Lee KW; Kim YJ; Oh DY; Kim JH; Im SA; Lee JS Acta Oncol; 2009; 48(3):385-90. PubMed ID: 18855156 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]